Courtney, Kevin D.

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 816

Targeting renal cell carcinoma with a HIF-2 antagonist

Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 709

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 393

Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo

Courtney, K. D., Bezwada, D., Mashimo, T., Pichumani, K., Vemireddy, V., Funk, A. M., Wimberly, J., McNeil, S. S., Kapur, P., Lotan, Y., et al. (2018) · Cell Metabolism

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 280

HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma

Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 188

Localization and Phosphorylation of Abl-Interactor Proteins, Abi-1 and Abi-2, in the Developing Nervous System

Courtney, K. D., Grove, M., Vandongen, H., Vandongen, A., LaMantia, A.-S., & Pendergast, A. M. (2000) · Molecular and Cellular Neuroscience

Protein Kinase Regulation and GTPase SignalingAxon Guidance and Neuronal Signaling

Cited by 78

Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).

De Bono, J. S., Fong, L., Beer, T. M., Gao, X., Geynisman, D. M., Burris III, H. A., Strauss, J. F., Courtney, K. D., Quinn, D. I., VanderWeele, D. J., et al. (2021) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 39

DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).

Parsonson, A. O., Gandhi, C., Henick, B. S., Schmidt, A. L., Ye, D., Amin, H., Wise-Draper, T. M., Courtney, K. D., Tam, L., Jiang, S., et al. (2025) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 9

A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Wang, K., Wallace, E., Josey, J. A., et al. (2016) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 7